Literature DB >> 1706386

Characterization of the human complement receptor 2 (CR2, CD21) promoter reveals sequences shared with regulatory regions of other developmentally restricted B cell proteins.

E J Rayhel1, M H Dehoff, V M Holers.   

Abstract

Expression of human complement receptor 2 (CR2, CD21, C3d,g/EBV receptor) is developmentally restricted on human B lymphocytes to cells of the late-pre and mature stages. CR2 is also a member of the genetically linked regulators of complement activation family found on human chromosome 1q32. Regulators of complement activation proteins are variably expressed in plasma, on cell membranes, and in nonvascular extracellular fluid sites. To begin to understand the mechanisms that control both tissue specific and B cell developmental restriction of CR2 expression, we have cloned and characterized the CR2 promoter upstream of a single apparent transcriptional initiation site. Within this region are sequences with significant similarity to previously characterized TATA, SP1, AP-2, AP-1-like, and Ig enhancer E motif DNA protein binding sites, in addition to direct and inverted repeats. Significant regions of identity are also found between CR2 promoter sequences and those of the CD23 promoter, another protein whose expression is developmentally restricted on B cells. The CR2 promoter will direct transcription of the reporter gene chloramphenicol acyltransferase when transiently transfected into the human Raji B cell line. Therefore, we have identified the promoter for a human B cell protein whose expression is developmentally restricted. Further analysis of this region and the transcriptional regulation of CR2 gene expression should lead to significant insights into the molecular mechanisms by which B cells mature and are activated.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1706386

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  8 in total

1.  Epstein-Barr virus EBNA3C represses Cp, the major promoter for EBNA expression, but has no effect on the promoter of the cell gene CD21.

Authors:  S A Radkov; M Bain; P J Farrell; M West; M Rowe; M J Allday
Journal:  J Virol       Date:  1997-11       Impact factor: 5.103

Review 2.  Molecular structure and expression of anthropic, ovine, and murine forms of complement receptor type 2.

Authors:  Dong Liu; Jian-Ying Zhu; Zhong-Xiang Niu
Journal:  Clin Vaccine Immunol       Date:  2008-04-09

3.  Focused transcription from the human CR2/CD21 core promoter is regulated by synergistic activity of TATA and Initiator elements in mature B cells.

Authors:  Rhonda L Taylor; Mark N Cruickshank; Mahdad Karimi; Han Leng Ng; Elizabeth Quail; Kenneth M Kaufman; John B Harley; Lawrence J Abraham; Betty P Tsao; Susan A Boackle; Daniela Ulgiati
Journal:  Cell Mol Immunol       Date:  2015-02-02       Impact factor: 11.530

4.  Heterogeneous nuclear ribonucleoprotein D0B is a sequence-specific DNA-binding protein.

Authors:  M Tolnay; L A Vereshchagina; G C Tsokos
Journal:  Biochem J       Date:  1999-03-01       Impact factor: 3.857

5.  Transcriptional effects of a lupus-associated polymorphism in the 5' untranslated region (UTR) of human complement receptor 2 (CR2/CD21).

Authors:  Mark N Cruickshank; Mahdad Karimi; Rhonda L Mason; Emily Fenwick; Tim Mercer; Betty P Tsao; Susan A Boackle; Daniela Ulgiati
Journal:  Mol Immunol       Date:  2012-06-04       Impact factor: 4.407

6.  Deletion of putative intronic control sequences does not alter cell or stage specific expression of Cr2.

Authors:  Kirstin M Roundy; Janis J Weis; John H Weis
Journal:  Mol Immunol       Date:  2009-09-09       Impact factor: 4.407

Review 7.  Transcriptional control of complement receptor gene expression.

Authors:  Brian K Martin
Journal:  Immunol Res       Date:  2007       Impact factor: 4.505

8.  New nucleotide sequence data on the EMBL File Server.

Authors: 
Journal:  Nucleic Acids Res       Date:  1991-07-11       Impact factor: 16.971

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.